SCHEMBL14745735

SCHEMBL14745735

CCc1c(-c2ccc3c(c2)c(C#N)c(Cl)n3C)nc(OCc2ccccc2)c(C(=O)OC)c1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.40
AS3MT Q9HBK9 1/20 0.40
MAPT P10636 6/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
SQOR Q9Y6N5 1/20 0.35
PLA2G2A P14555 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745357 0.88 AS3MT (0.38) CNR1AS3MTMAPTTDP1ALDH1A1
SCHEMBL14758124 0.87 CNR1 (0.39) CNR1AS3MTMAPTALDH1A1GAA
SCHEMBL14745159 0.84 IMPDH2 (0.42) CNR1MAPTTDP1LMNAHPGD
SCHEMBL14744837 0.83 CNR1 (0.44) CNR1MAPTTDP1ALDH1A1GAA
SCHEMBL14745116 0.81 AS3MT (0.39) CNR1AS3MTTDP1ALDH1A1LMNA
SCHEMBL14745654 0.80 CNR1 (0.41) CNR1MAPTTDP1ALDH1A1GAA
SCHEMBL14745778 0.77 IMPDH2 (0.42) CNR1
SCHEMBL14745658 0.76 CNR1 (0.39) CNR1KDM4E
SCHEMBL14758147 0.75 MAPK8 (0.37) CNR1MAPTTDP1ALDH1A1LMNA
SCHEMBL14741171 0.71 ADORA3 (0.51) CNR1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP CNR1 4586/4885AS3MT 1865/4885MAPT 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.